Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 9/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21060650 | 0.84 | GRIN1 (0.47) | QPCTQPCTLERBB2RECQLEGFR | |
| SCHEMBL2443709 | 0.80 | NPBWR1 (0.47) | QPCTQPCTLRECQLGRIN1GRIN2B | |
| SCHEMBL21058132 | 0.72 | RECQL (0.46) | ERBB2RECQLEGFR | |
| SCHEMBL21058074 | 0.72 | EGFR (0.50) | ERBB2RECQLEGFRGRIN1GRIN2B | |
| SCHEMBL21060789 | 0.72 | RECQL (0.38) | QPCTQPCTLERBB2RECQLEGFR | |
| SCHEMBL384816 | 0.70 | HTR2A (0.46) | QPCTQPCTL | |
| SCHEMBL30018490 | 0.69 | MAP4K1 (0.40) | QPCTQPCTLERBB2EGFRGRIN1 | |
| SCHEMBL21060715 | 0.69 | BRD4 (0.39) | QPCTQPCTLRECQL | |
| SCHEMBL27787592 | 0.68 | RECQL (0.46) | ERBB2RECQLEGFREPHX2PPARG | |
| SCHEMBL19654950 | 0.68 | RECQL (0.47) | ERBB2RECQLEGFRMAPK1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728219-B1 | SUBSTITUTED PYRROLIDINE AMIDES I | GRUENENTHAL GMBH (DE) | 2022-04-13 | — | — | EP | disclosed |
| EP-3728219-A1 | SUBSTITUTED PYRROLIDINE AMIDES I | Grünenthal GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111556867-A | Substituted pyrrolidine amides I | 格吕伦塔尔有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-10626106-B2 | Substituted pyrrolidine amides I | GRUENENTHAL GMBH (DE) | 2020-04-21 | — | — | US | disclosed |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626106-B2 | Substituted pyrrolidine amides I | NR3C1, NR3C2, NR5A1 | LOX 4363/4885LOXL2 4713/4885QPCT 457/4885 |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | NR3C1, NR3C2, NR5A1 | LOX 4363/4885LOXL2 4713/4885QPCT 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.